Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cognitive impairment in multiple sclerosis.
Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis.
EMD Serono
Final results from the Betaseron (interferon β-1b) Pregnancy Registry: a prospective observational study of birth defects and pregnancy-related adverse events.
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
Interferons beta have vasoconstrictive and procoagulant effects: A woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis.
A novel pH-sensitive interferon-β (INF-β) oral delivery system for application in multiple sclerosis.
The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.
Control of oxidative stress and inflammation in sickle cell disease with the Nrf2 activator dimethyl fumarate.
Genzyme receives positive CHMP opinion in the European Union for once-daily, oral AUBAGIO® to treat relapsing-remitting multiple sclerosis
Withdrawal of the marketing authorization in the European Union
Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans.
The Swiss Multiple Sclerosis Cohort-Study (SMSC): A Prospective Swiss Wide Investigation of Key Phases in Disease Evolution and New Treatment Options.
Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Dose comparison trial of sustained-release fampridine in multiple sclerosis.
Dimethyl fumarate modulates antioxidant and lipid metabolism in oligodendrocytes.
Power estimation for non-standardized multisite studies.
B cells and multiple sclerosis.
Daclizumab discontinue letter for the US market
Potential short-term use of oral cladribine in treatment of relapsing-remitting multiple sclerosis.
Genzyme’s Lemtrada Approved by the FDA
Biogen Idec's long-acting beta interferon moves ahead in MS
lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C.

Pages